• ,

Vitiligo Market Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the Market

Vitiligo Market Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the Market
Vitiligo Market
DelveInsight’s “Vitiligo Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Vitiligo, historical and forecasted epidemiology as well as the Vitiligo market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

DelveInsight’s “Vitiligo Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Vitiligo, historical and forecasted epidemiology as well as the Vitiligo market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Vitiligo market report provides current treatment practices, emerging drugs, Vitiligo market share of the individual therapies, and current and forecasted Vitiligo market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Vitiligo treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Vitiligo market.

 

Some of the key facts of Vitiligo Market Report:

  • Vitiligo develops at all ages and affects both sexes equally. Despite the same prevalence ratio of 1:1 in males and females, the ratio of treatment requests is 1:2. This signifies that females seek treatments more frequently, which apparently might be due to the ramifications of greater social burden (Alikhan et al. 2011).
  • The prevalence of vitiligo increases with age and ranges from 0.06% to 2.28% in the general population and from 0% to 2.16% in children.
  • The study also found that there was a higher prevalence of hypothyroidism in people with vitiligo.
  • US population-based prevalence estimate of overall (diagnosed and undiagnosed combined) vitiligo in adults is between 0.76% (1.9 million cases in 2020) and 1.11% (2.8 million cases in 2020).

Key benefits of the Vitiligo Market report:

 

  • In the coming years, the Vitiligo market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Vitiligo R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition      
  • Major players are involved in developing therapies for Vitiligo. The launch of emerging therapies will significantly impact the Vitiligo market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Vitiligo
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Got queries? Click here to know more about the Vitiligo Market Landscape 

Vitiligo Overview

Vitiligo is a common acquired skin disorder that results from the loss of melanocytes from the epidermis and clinically manifests as well-demarcated white patches on the body. The condition is usually associated with few autoimmune disorders, with thyroid abnormalities are the commonest one. The cause is unknown but might involve genetic factors, autoimmunity, neurologic factors, toxic metabolites, and lack of melanocyte growth factors. There are different clinical variants of vitiligo which are Trichrome, Marginal inflammatory, and Quadrichrome vitiligo.

It can appear at any age from child to adulthood but peak incidence is reported in the second and third decades. The age of onset usually varies between the sexes. Its prevalence is approximately 0.1% to 2% of people including adults and children worldwide and it affects all races equally. The diagnosis of vitiligo is usually made on clinical features, through a wood light examination biopsy is sometimes helpful to differentiate vitiligo from other hypopigmented or depigmented disorders. The histopathological examination of the skin reveals the absence of melanocytes and complete epidermal pigmentation loss. Superficial perifollicular and perivascular lymphocytic infiltrates may be present at the margin of the vitiligo lesions, due to the cell-mediated process that destroys the melanocytes.

Vitiligo  Epidemiological Insights:

  • Vitiligo is the most common depigmenting skin disorder, with an estimated prevalence of 0.5–2% of the population in both adults and children worldwide.  the current US population-based prevalence estimate of overall (diagnosed and undiagnosed combined) vitiligo in adults is between 0.76% (1.9 million cases in 2020) and 1.11% (2.8 million cases in 2020). And between 0.17% and 0.77% indicates the most probable spectrum of vitiligo prevalence in Germany. Childhood-onset vitiligo is common and affects 32% of patients, with most (89%) having a disease onset after the age of four years. NSV can occur at any age, whereas SV tends to occur in young patients. SV accounts for 5-16% of overall cases of vitiligo.
  • Non-segmental vitiligo develops at all ages but usually occurs in young people between the ages of 10 and 30 years. Twenty-five percent of vitiligo patients develop the disease before the age of 10 years, almost half of patients with vitiligo develop the disease before the age of 20 years and nearly 70–80% before the age of 30 years.
  • Segmental vitiligo tends to occur at a younger age than NSV before the age of 30 years in 87% of cases and before the age of 10 years in 41.3%.  In SV, the most commonly involved areas are the face (51.1%), anterior trunk (21.5%), and extremities (10.8%).

Vitiligo  Epidemiological Segmentation

  • Total Vitiligo prevalent population
  • Total Vitiligo prevalence based on subtype 
  • Vitiligo age-specific prevalent cases 
  • Vitiligo diagnosed and treated cases 
  • Vitiligo prevelant cases based on gender

Vitligo Market Outlook 

The Vitiligo market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Vitiligo market trends by analyzing the impact of current Vitiligo therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

 

This segment gives a thorough detail of the Vitiligo market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Vitiligo market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

 

According to DelveInsight, the Vitiligo market in 7MM is expected to witness a major change in the study period 2019-2032.

 

Learn more by requesting for sample @ Vitiligo  Market Landscape

 

Vitiligo Key Companies  

 

  • Reistone Biopharma Company Limited
  • Incyte Corporation
  • Dermavant Sciences GmbH
  • Sun Pharmaceutical
  • And many more 

Vitiligo Key Therapies 

  • SHR0302 ointment
  • Ruxolitinib cream
  • Cerdulatinib 0.37% gel
  • AS012  
  • and many more

Table of Contents

  • Key Insights 
  • Report Introduction 
  • Executive Summary of Vitiligo  Market 
  • Disease Background and Overview
  • Epidemiology and patient population
  • The United States 
  • EU 5
  • Vitiligo  Market   Emerging Therapies
  • Vitiligo  Market  Market Outlook
  • Market Access and Reimbursement of Therapies
  • Appendix
  • Vitiligo  Market  Report Methodology
  • DelveInsight Capabilities
  • Disclaimer
  • About DelveInsight

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/